Makris Konstantinos, Spanou Loukia
Clinical Biochemistry Department, KAT General Hospital, Kifissia, Athens, 14561, Greece.
Clin Biochem Rev. 2016 Dec;37(4):153-175.
Acute kidney injury (AKI) is a significant independent risk factor for morbidity and mortality. In the last ten years a large number of publications have highlighted the limitations of traditional approaches and the inadequacies of conventional biomarkers to diagnose and monitor renal insufficiency in the acute setting. A great effort was directed not only to the discovery and validation of new biomarkers aimed to detect AKI more accurately but also to standardise the definition of AKI. Despite the advances in both areas, biomarkers have not yet entered into routine clinical practice and the definition of this syndrome has many areas of uncertainty. This review will discuss the controversies in diagnosis and the potential of novel biomarkers to improve the definition of the syndrome.
急性肾损伤（AKI）是发病率和死亡率的一个重要独立危险因素。在过去十年中，大量出版物强调了传统方法的局限性以及传统生物标志物在急性情况下诊断和监测肾功能不全的不足之处。人们不仅大力致力于发现和验证旨在更准确检测AKI的新生物标志物，还致力于规范AKI的定义。尽管在这两个领域都取得了进展，但生物标志物尚未进入常规临床实践，并且该综合征的定义仍存在许多不确定的方面。本综述将讨论诊断方面的争议以及新型生物标志物改善该综合征定义的潜力。
